Clinical and Immunological Investigations of Subtypes of Autism
The purpose of this study is to learn more about autism and its subtypes. Autism is a developmental disorder in which children have problems with communication and social skills and display restricted interests and repetitive behaviors.
This study has several goals. One aim is to look at types of autism that are known, such as the regressive subtype, (where skills are lost). We will explore whether there is a unique change in immune functioning related to this subtype. Another aim is to serve as one of the sites that will pilot a larger natural history study, entitled Autism Phenome Project. The goal is to further understand autism by identifying other subtypes.
We will look at several types of medical issues that may be related to autism, including immunologic problems. Children will be followed over the course of several years. We aim to capture medical problems that may be related to autism as they develop, and study outcomes in areas such as behavior and language, in order to explore known and new subtypes of autism.
Normally developing children (aged 1) with autism (age 1, and developmental delays other than autism (age 1), may be eligible for this study.
Depending on each child's study group and age, participants may undergo the following tests and procedures:
- Medical and developmental history, physical examination, psychological, cognitive and medical tests to assess symptoms of autism or other developmental disorders, photographs of the child's face, collection of hair, urine and baby teeth samples. If available, hair samples from the baby's first haircut and from the biological mother's hair are also collected.
- Overnight electroencephalogram (EEG): A special cap with electrodes is placed on the child's head to measure brain waves (brain electrical activity) while the child sleeps in the hospital overnight. Healthy volunteers do not undergo this procedure.
- Magnetic resonance imaging (MRI) scan: The child stays in the scanner, lying still for 10 to 15 minutes at a time. Since it may be difficult for the child to lie still, the test may be scheduled for a time when the child is likely to be sleepy, or the child may be sedated.
- Lumbar puncture (for children in the autism). This test and the MRI may be done under sedation.
Follow-up visits are scheduled at different intervals, depending on study group, age and aspect of the study the child is enrolled in. The visits include a short interview session with the child's caregiver and assessment of the child's development and behavior. Some of the assessment measures used during the baseline examination are repeated, including symptoms ratings, behavioral tests and a blood test. For some children, the final visit will include repeats of the medical procedures.
Autism Spectrum Disorders
|Study Design:||Time Perspective: Prospective|
|Official Title:||Clinical and Immunological Investigations of Subtypes of Autism|
- Behavioral profiles [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
- Immune markers [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
- Sleep/EEG findings [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
- Neuroimaging findings [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
- Other laboratory findings [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
- Genetic abnormalities [ Time Frame: 6 to 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||February 2006|
The current investigation will focus on the interrelationship between regression in autism and immune dysfunction. We propose to conduct a longitudinal natural history of 140 children with autism: 50 children with strictly defined regression, 50 with no history of regression, and an additional 40 children initially recruited in a pilot study for the Autism Phenome Project. We will also evaluate and follow 75 typically developing children, and 50 children with Development Delay. Subjects will be 12-60 months of age at study entry in order to capture regression as close to its onset as possible. Systematic prospective evaluations will be utilized in order to provide validation to the phenomenon of regression in autism, determine diagnostic and functional outcomes, and evaluate behavioral, medical and immunologic functioning. These evaluations will include comprehensive medical history, behavioral assessment, physical and neurologic examination, sleep EEG, structural MRI, blood work for laboratory assays, and for some children, lumbar puncture. In an investigation of potential immunologic abnormalities and associated neuroinflammation, repeated assessments are necessary to determine whether both behavioral and/or immunologic parameters are due to state versus trait alterations: elements of these assessments will be conducted every 6 to 12 months, depending on the child's age.
Our objective is to determine if there is a unique alteration in immune function among autistic children with a regressive clinical course. Our primary hypothesis is that at least some children with regressive autism will have abnormalities in immune function. These abnormalities will not be found among autistic children without a regressive course nor will they be found among children without an autistic spectrum disorder. Our specific aims are:
Specific Aim #1: To characterize and validate the regressive phenotype in children with autism.
Working hypothesis: Children with the diagnosis of autism who had a regressive clinical course can be reliably distinguished from children with non-regressive autism, Rett's Disorder and healthy children. When compared to children with non-regressive autism, the history of children in the regressive group will consist of similar or higher skill levels prior to regression, and lower skill levels following regression.
Specific Aim #2: To characterize the immune response in children with autism.
Working Hypothesis 2a: Distinct immunologic responses and cytokine abnormalities will be evident in children in the regressive autism sample, but not in the non-regressive autism, Rett's Disorder, or typically developing samples.
Working Hypothesis 2b: MRI scans will reveal regional neuroinflammation among children in the regressive autism sample, but not in the non-regressive autism, Rett's Disorder, or typically developing samples.
Specific Aim #3: To identify neurobiologic markers for autism through the techniques of metabolomics, proteomics and genomics (e.g. gene expression profiles).
Working hypothesis: These neurobiologic markers will reliably differentiate between regressive autism, non-regressive autism, Rett's Disorder, and typically developing children.
In addition, although progress has been made in identifying children affected by autism, little attention has been paid to the different manifestations of autism (or autisms). As has been demonstrated in "diabetes" and "cancer", it is expected that the differences between individuals with autism may be as informative as their behavioral similarities. Complementing this study that investigates one possible subtype (regression), we propose to pilot a phenomenologic investigation to identify other biological and behavioral subgroups of autistic individuals, in order to facilitate investigations of etiology, pathophysiology, treatment and prevention. This will be done as a collaborative project with the M.I.N.D. Institute in Sacramento, California (approval for the collaborative protocols and data sharing was prevousl given by both NIMH and the University of California-Davis IRBs). The phenomenoligic investigation will evaluate the same children specified in the other aims (if they sign the consent to share their data with the MIND Institute) as well as data from typically developing children and developmental delays that consent for this.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00298246
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Susan E Swedo, M.D.||National Institute of Mental Health (NIMH)|